Zealand Pharma grants sign-on warrants and performance stock units under the employee warrant program and management long-term incentive program
December 02, 2022 12:00 ET
|
Zealand Pharma
Company announcement – No. 55/ 2022 Zealand Pharma grants sign-on warrants and performance stock units under the employee warrant program and management long-term incentive program ...
Total number of shares and voting rights in Zealand Pharma at November 30, 2022
November 30, 2022 11:05 ET
|
Zealand Pharma
Company announcement – No. 54 / 2022 Total number of shares and voting rights in Zealand Pharma at November 30, 2022 Copenhagen, Denmark and Boston, MA, U.S. November 30, 2022 – Zealand Pharma A/S...
Zealand Pharma Announces Financial Results for the First Nine Months of 2022
November 10, 2022 09:00 ET
|
Zealand Pharma
Company announcement No. 51 / 2022 Zealand Pharma Announces Financial Results for the First Nine Months of 2022 Copenhagen, Denmark November 10, 2022 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no....
Total number of shares and voting rights in Zealand Pharma at October 31, 2022
October 31, 2022 12:05 ET
|
Zealand Pharma
Company announcement – No. 48 / 2022 Total number of shares and voting rights in Zealand Pharma at October 31, 2022 Copenhagen, Denmark and Boston, MA, U.S. October 31, 2022 – Zealand Pharma...
Zealand Pharma major shareholder announcement: Polar Capital
October 11, 2022 11:05 ET
|
Zealand Pharma
Company announcement – No. 47 / 2022 Zealand Pharma major shareholder announcement: Polar Capital Copenhagen, Denmark and Boston, MA, 11 October 2022 – Zealand Pharma A/S (“Zealand”)...
Zealand Pharma major shareholder announcement: Van Herk Investments
October 10, 2022 11:12 ET
|
Zealand Pharma
Company announcement – No. 46 / 2022 Zealand Pharma major shareholder announcement: Van Herk Investments Copenhagen, Denmark and Boston, MA, 10 October 2022 – Zealand Pharma A/S...
Zealand Pharma announces directed issue and private placement of approximately 4.5m new shares
October 04, 2022 11:05 ET
|
Zealand Pharma
Company announcement – No. 43 / 2022 Zealand Pharma announces directed issue and private placement of approximately 4.5m new shares NOT FOR RELEASE, PUBLICATION OR...
Zealand Pharma Announces Oral Presentation of Phase 2 Data for BI 456906 at the 58th Annual Meeting of the European Association for the Study of Diabetes (EASD)
September 21, 2022 08:15 ET
|
Zealand Pharma
Press release – No. 6 / 2022 Zealand Pharma Announces Oral Presentation of Phase 2 Data for BI 456906 at the 58th Annual Meeting of the European Association for the Study of Diabetes (EASD) ...
Zealand Pharma Presents Data from Phase 3 Trial of Dasiglucagon in Congenital Hyperinsulinism at the 60th Annual ESPE Meeting
September 19, 2022 02:00 ET
|
Zealand Pharma
Press release – No. 5 / 2022 Zealand Pharma Presents Data from Phase 3 Trial of Dasiglucagon in Congenital Hyperinsulinism at the 60th Annual ESPE Meeting Dasiglucagon significantly...
Zealand Pharma Announces Global License and Development Agreement with Novo Nordisk for ZEGALOGUE® (dasiglucagon)
September 07, 2022 02:00 ET
|
Zealand Pharma
Company announcement – No. 38 / 2022 Agreement includes an upfront payment, development, regulatory, manufacturing and sales-based milestones of up to DKK 290 million to Zealand in addition to...